Table 1 Comparison of CR, ORR, PFS, DoR, and OS among the different BRAF and MEK inhibitors combination
BRAFi/MEKi combination | Study | CR (%) | ORR (%) | mPFS (HR) | mDoR | mOS (HR) |
|---|---|---|---|---|---|---|
Dabrafenib + trametinib | Phase III | 13 | 69 | 11.0 (0.67) | 12.9 | 25.1 (0.71) |
Vemurafenib + cobimetinib | Phase III | 15.8 | 69.6 | 12.2 (0.58) | 12.9 | – |
Encorafenib + binimetinib | Phase I | 12.7 | 74.5 | 11.3 | – | – |